We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Pulmonary arterial hypertension (PAH) is a rare but serious condition characterized by high blood pressure in the arteries that supply the lungs, which can lead to symptoms like shortness of breath, fatigue, and chest pain.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
